Nobody Understands Peptides
Peptides range from FDA-approved drugs to unproven research-vial powders, and the word itself tells you nothing about whether a given one is safe, legal, or effective. Judge each peptide by a specific claim, route, human evidence, and regulatory status, not by the category name. For many peptides people are searching right now, the marketing runs well ahead of the human data, and a clinic being able to source something is not the same as that thing being shown to work.
Format, not grade
Peptide just means a short chain of amino acids. Insulin is a peptide, semaglutide is a peptide, and so is a gray-market powder with no human trials.
Access is not evidence
A compounding pharmacy filling a prescription is not scientific endorsement. A 503A bulk-substance review is not FDA approval and not proof that a peptide works.
Grade the claim
The useful question is not whether peptides are good or bad. It is the exact molecule, exact claim, route, human evidence, regulatory status, and source risk.
The Peptide Decoder
One row per peptide plus claim. The same molecule can have strong evidence for one indication and weak evidence for a wellness claim or a gray-market source.
Availability does not upgrade the evidence.
Approval, compounding, research-use, and gray-market supply are separate clinical facts. This table keeps them separate.
Evidence grades
Grades describe the claim, not the molecule as a whole.
- A
- FDA-approved or guideline-level use with large, replicated human RCTs and meaningful clinical endpoints.
- B
- Multiple credible human controlled trials, consistent benefit, acceptable safety signal, but not necessarily approved for the exact use.
- C
- Some human clinical evidence, but small, old, regional, non-replicated, inconsistent, or not FDA/EMA-grade.
- D
- Mostly mechanistic/preclinical evidence, human biomarker/observational data, tiny uncontrolled pilots, or class-adjacent evidence.
- F
- Public claims substantially outrun credible human evidence for that use.
- N/A
- Framework, regulatory, or quality-literacy row, not an efficacy claim.
- Claim
- the exact promise being made
- Evidence
- what has been shown in humans
- Access
- approval, compounding, investigation, or gray market
- First move
- the better-studied alternative
Start here
These rows explain most of the confusion: approved peptide drugs, repair peptides, investigational drugs, salts, and research vials.
01
Semaglutide / tirzepatide
Summary anchor: weight loss, diabetes, cardiometabolic risk
Real peptide medicine exists. That does not validate every peptide vial or every source.
strong human evidence
FDA-approved branded; lower risk
02
BPC-157
Injury recovery, tendon/ligament healing, joint pain, gut repair
Animal healing signals are not a return-to-sport plan.
mostly mechanism
503A compounding; highest risk
03
TB-500 / thymosin beta-4 fragment
Injury recovery, tendon/muscle healing, Wolverine stack
Do not borrow evidence from a cousin molecule.
mostly mechanism
503A compounding; highest risk
04
Semaglutide / tirzepatide
Compounded access during shortage or affordability constraints
The evidence may belong to the molecule, but the risk may belong to the source.
framework row
Shortage compounding; varies
05
Retatrutide
Weight loss / metabolic pipeline drug
Retatrutide belongs in the Atlas precisely because trial-stage is not the same as ready-to-buy.
credible human signal
Investigational; moderate risk
06
Retatrutide
Research-use or gray-market retatrutide
Pipeline hype is how evidence leaks into unsafe access.
claim outruns evidence
Gray-market; highest risk
07
Semaglutide / tirzepatide
Research-use or gray-market GLP-1 products
The evidence may belong to the molecule; the risk may belong to the source.
claim outruns evidence
Gray-market; highest risk
08
Semaglutide salt forms
Semaglutide sodium/acetate is basically the same
A similar name is not the same active ingredient.
claim outruns evidence
Gray-market; highest risk
All Decoder rows
Rows that still need a final source refresh stay out of this live table until the public claim is ready.
| Grade | Peptide | Claim | Evidence | Access | First move |
|---|---|---|---|---|---|
| A | DEC-001 Semaglutide / tirzepatide | Summary anchor: weight loss, diabetes, cardiometabolic risk Real peptide medicine exists. That does not validate every peptide vial or every source. | Large human RCTs and FDA-approved indications; outcomes vary by drug and indication. | FDA-approved drugs for specific indications FDA-approved branded; lower risk | Standard obesity/diabetes/cardiometabolic care |
| D | DEC-003 BPC-157Guide planned | Injury recovery, tendon/ligament healing, joint pain, gut repair Animal healing signals are not a return-to-sport plan. | Mostly preclinical; one tiny uncontrolled human knee-pain series; recruiting Phase 2 hamstring trial with no posted results as of 2026-07-07. | Not FDA-approved; reviewed by FDA PCAC for 503A bulk-substance question 503A compounding; highest risk | Diagnosis, load management, progressive rehab, imaging when indicated, evidence-based sports medicine |
| D | DEC-004 TB-500 / thymosin beta-4 fragmentGuide planned | Injury recovery, tendon/muscle healing, Wolverine stack Do not borrow evidence from a cousin molecule. | Direct injected TB-500 human evidence is weak; marketing often borrows full-length thymosin beta-4 or topical/ophthalmic data. | Not FDA-approved; reviewed by FDA PCAC for wound-healing bulk-substance question 503A compounding; highest risk | Diagnosis, rehab, objective return-to-play criteria |
| D | DEC-005 KPVGuide planned | Gut inflammation, IBD-style claims, eczema/psoriasis/acne, systemic inflammation Plausible anti-inflammatory biology is not the same thing as a patient-ready drug. | Plausible preclinical gut/skin anti-inflammatory models; FDA notes no identified human exposure data for KPV drug products. | Not FDA-approved; reviewed by FDA PCAC for wound healing and inflammatory conditions 503A compounding; high risk | Standard GI/dermatology workup and evidence-based anti-inflammatory care |
| D | DEC-006 MOTS-cGuide planned | Metabolic flexibility, insulin sensitivity, exercise-mimetic effects Exercise-mimetic biology is interesting. It is not a treatment until human outcome data exist. | Foundational animal/metabolic biology, human association signals, early analog trials; no established clinical-outcome use. | Not FDA-approved; reviewed by FDA PCAC for obesity and osteoporosis 503A compounding; high risk | Exercise, nutrition, sleep, GLP-1/GIP care when clinically indicated, metabolic workup |
| D | DEC-007 MOTS-cGuide planned | Weight loss or GLP-1 alternative MOTS-c is not an Ozempic alternative. | No convincing human weight-loss outcome evidence comparable to approved obesity medications. | Not FDA-approved; PCAC/503A question only 503A compounding; high risk | Evidence-based obesity care, GLP-1/GIP agents when appropriate |
| D | DEC-008 Emideltide / DSIPGuide planned | Sleep depth, chronic insomnia, stress/HPA axis The name is better than the evidence. | Old, small, mixed human sleep studies; not modern replicated insomnia evidence. | Not FDA-approved; reviewed by FDA PCAC for insomnia, opioid withdrawal, narcolepsy 503A compounding; high risk | CBT-I, sleep apnea screen, behavioral sleep treatment, clinically appropriate medications |
| D | DEC-009 Emideltide / DSIPGuide planned | Opioid withdrawal, pain, mood/cortisol support Withdrawal and pain claims need modern evidence, not nostalgia for old peptide studies. | Old/open-label or pilot signals; not modern addiction or pain-care evidence. | Not FDA-approved; PCAC/503A question only 503A compounding; high risk | Evidence-based addiction medicine, pain evaluation, sleep and mental-health care |
| C | DEC-010 SemaxGuide planned | Stroke/cerebrovascular recovery Best signal on the list, still not a US-standard stroke drug. | Best human signal among PCAC seven, but largely older/regional literature, not modern multicenter FDA/EMA-grade trials. | Not FDA-approved in US; reviewed by FDA PCAC for cerebral ischemia, migraine, trigeminal neuralgia 503A compounding; high risk | Standard acute stroke and rehab care; neurology-guided treatment |
| D | DEC-011 SemaxGuide planned | Focus, ADHD, nootropic, brain fog, productivity Stroke signal does not make a plug-and-play focus peptide. | Mostly extrapolated from neurologic/stroke literature plus mechanistic/animal data; not healthy-person productivity evidence. | Not FDA-approved; wellness/nootropic market 503A compounding; high risk | ADHD evaluation, sleep, mood, iron/B12/thyroid where appropriate, evidence-based stimulants/nonstimulants when indicated |
| D | DEC-012 EpitalonGuide planned | Circadian/longevity/telomere biology A telomere story is not a longevity treatment. | Cell, animal/primate, older gerontology, and narrow research-tradition evidence; no robust human healthspan outcomes. | Not FDA-approved; reviewed by FDA PCAC for insomnia 503A compounding; high risk | Sleep/circadian basics, light timing, exercise, metabolic and cardiovascular prevention |
| F | DEC-013 EpitalonGuide planned | Insomnia treatment The telomere story is not an insomnia trial. | No convincing controlled human insomnia evidence matching the public claim. | Not FDA-approved; PCAC reviewed insomnia use 503A compounding; high risk | CBT-I, sleep apnea screen, circadian rhythm workup, evidence-based insomnia care |
| N/A | DEC-014 Peptide COAGuide planned | 99% pure means safe A COA can support identity or purity. It cannot prove that an injectable is safe for you. | Quality-literacy framework, not efficacy evidence. | COA varies by vendor/lab and does not establish clinical appropriateness Framework; varies | Regulated pharmacy supply, sterile compounding standards, clinician oversight |
| N/A | DEC-015 FDA / 503A statusGuide planned | If a clinic can get it, it must be proven Access is not evidence. | Regulatory-literacy framework based on FDA/PCAC materials. | 503A/PCAC review is not approval or efficacy evidence Framework; not a route claim | FDA-approved drug pathway, clinical trials, supervised care |
| N/A | DEC-038 Semaglutide / tirzepatideGuide planned | Compounded access during shortage or affordability constraints The evidence may belong to the molecule, but the risk may belong to the source. | Access/quality row, not an efficacy row. | 503A/503B/shortage-dependent access category, source must be verified at time of writing Shortage compounding; varies | FDA-approved branded supply when accessible; clinician/pharmacy due diligence if compounded |
| B | DEC-039 RetatrutideGuide planned | Weight loss / metabolic pipeline drug Retatrutide belongs in the Atlas precisely because trial-stage is not the same as ready-to-buy. | Promising human trial-stage evidence; not an approved DIY peptide. | Investigational drug category, not gray-market wellness access Investigational; moderate risk | Approved obesity medications or clinical trial enrollment |
| F | DEC-040 RetatrutideGuide planned | Research-use or gray-market retatrutide Pipeline hype is how evidence leaks into unsafe access. | Efficacy trial signal does not validate non-prescribed supply; source quality is the main claim problem. | Research-use/gray-market access Gray-market; highest risk | Do not self-source; consider approved options or clinical trials |
| F | DEC-041 Semaglutide / tirzepatideGuide planned | Research-use or gray-market GLP-1 products The evidence may belong to the molecule; the risk may belong to the source. | Approved-drug evidence does not validate non-prescribed supply, concentration, sterility, or labeling. | Gray-market/research-use access Gray-market; highest risk | FDA-approved branded supply when accessible; clinician/pharmacy due diligence if compounded |
| F | DEC-042 Semaglutide salt formsGuide planned | Semaglutide sodium/acetate is basically the same A similar name is not the same active ingredient. | FDA states salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than approved semaglutide products and should not be used for compounding. | Unapproved/salt-form access problem Gray-market; highest risk | Avoid salt-form substitutions; use approved or appropriately supervised regulated pathways |
| B | DEC-043 RetatrutideGuide planned | Type 2 diabetes / glycemic control Trial data can be strong before a drug is available medicine. | Phase 2 and phase 3 human trials support glycemic and weight effects, but regulatory approval/access status remains separate. | Investigational drug category, not approved access Investigational; moderate risk | Approved diabetes/obesity medications or clinical trial enrollment |
| B | DEC-044 RetatrutideGuide planned | MASLD / liver fat reduction Liver-fat signal is exciting; do not translate it into a generic longevity claim. | Phase 2a substudy shows strong liver-fat reduction by MRI-PDFF; not yet a biopsy-proven MASH/fibrosis-outcome or longevity claim. | Investigational drug category, not approved access Investigational; moderate risk | MASLD workup, weight-loss therapy, cardiometabolic risk management, clinical trial enrollment |
DEC-001
Semaglutide / tirzepatide
Summary anchor: weight loss, diabetes, cardiometabolic risk
Real peptide medicine exists. That does not validate every peptide vial or every source.
- Evidence
- Large human RCTs and FDA-approved indications; outcomes vary by drug and indication.
- Access
- FDA-approved drugs for specific indications
- First move
- Standard obesity/diabetes/cardiometabolic care
FDA-approved branded; lower risk · Related guide
DEC-003
BPC-157
Injury recovery, tendon/ligament healing, joint pain, gut repair
Animal healing signals are not a return-to-sport plan.
- Evidence
- Mostly preclinical; one tiny uncontrolled human knee-pain series; recruiting Phase 2 hamstring trial with no posted results as of 2026-07-07.
- Access
- Not FDA-approved; reviewed by FDA PCAC for 503A bulk-substance question
- First move
- Diagnosis, load management, progressive rehab, imaging when indicated, evidence-based sports medicine
503A compounding; highest risk · Guide planned
DEC-004
TB-500 / thymosin beta-4 fragment
Injury recovery, tendon/muscle healing, Wolverine stack
Do not borrow evidence from a cousin molecule.
- Evidence
- Direct injected TB-500 human evidence is weak; marketing often borrows full-length thymosin beta-4 or topical/ophthalmic data.
- Access
- Not FDA-approved; reviewed by FDA PCAC for wound-healing bulk-substance question
- First move
- Diagnosis, rehab, objective return-to-play criteria
503A compounding; highest risk · Guide planned
DEC-005
KPV
Gut inflammation, IBD-style claims, eczema/psoriasis/acne, systemic inflammation
Plausible anti-inflammatory biology is not the same thing as a patient-ready drug.
- Evidence
- Plausible preclinical gut/skin anti-inflammatory models; FDA notes no identified human exposure data for KPV drug products.
- Access
- Not FDA-approved; reviewed by FDA PCAC for wound healing and inflammatory conditions
- First move
- Standard GI/dermatology workup and evidence-based anti-inflammatory care
503A compounding; high risk · Guide planned
DEC-006
MOTS-c
Metabolic flexibility, insulin sensitivity, exercise-mimetic effects
Exercise-mimetic biology is interesting. It is not a treatment until human outcome data exist.
- Evidence
- Foundational animal/metabolic biology, human association signals, early analog trials; no established clinical-outcome use.
- Access
- Not FDA-approved; reviewed by FDA PCAC for obesity and osteoporosis
- First move
- Exercise, nutrition, sleep, GLP-1/GIP care when clinically indicated, metabolic workup
503A compounding; high risk · Guide planned
DEC-007
MOTS-c
Weight loss or GLP-1 alternative
MOTS-c is not an Ozempic alternative.
- Evidence
- No convincing human weight-loss outcome evidence comparable to approved obesity medications.
- Access
- Not FDA-approved; PCAC/503A question only
- First move
- Evidence-based obesity care, GLP-1/GIP agents when appropriate
503A compounding; high risk · Guide planned
DEC-008
Emideltide / DSIP
Sleep depth, chronic insomnia, stress/HPA axis
The name is better than the evidence.
- Evidence
- Old, small, mixed human sleep studies; not modern replicated insomnia evidence.
- Access
- Not FDA-approved; reviewed by FDA PCAC for insomnia, opioid withdrawal, narcolepsy
- First move
- CBT-I, sleep apnea screen, behavioral sleep treatment, clinically appropriate medications
503A compounding; high risk · Guide planned
DEC-009
Emideltide / DSIP
Opioid withdrawal, pain, mood/cortisol support
Withdrawal and pain claims need modern evidence, not nostalgia for old peptide studies.
- Evidence
- Old/open-label or pilot signals; not modern addiction or pain-care evidence.
- Access
- Not FDA-approved; PCAC/503A question only
- First move
- Evidence-based addiction medicine, pain evaluation, sleep and mental-health care
503A compounding; high risk · Guide planned
DEC-010
Semax
Stroke/cerebrovascular recovery
Best signal on the list, still not a US-standard stroke drug.
- Evidence
- Best human signal among PCAC seven, but largely older/regional literature, not modern multicenter FDA/EMA-grade trials.
- Access
- Not FDA-approved in US; reviewed by FDA PCAC for cerebral ischemia, migraine, trigeminal neuralgia
- First move
- Standard acute stroke and rehab care; neurology-guided treatment
503A compounding; high risk · Guide planned
DEC-011
Semax
Focus, ADHD, nootropic, brain fog, productivity
Stroke signal does not make a plug-and-play focus peptide.
- Evidence
- Mostly extrapolated from neurologic/stroke literature plus mechanistic/animal data; not healthy-person productivity evidence.
- Access
- Not FDA-approved; wellness/nootropic market
- First move
- ADHD evaluation, sleep, mood, iron/B12/thyroid where appropriate, evidence-based stimulants/nonstimulants when indicated
503A compounding; high risk · Guide planned
DEC-012
Epitalon
Circadian/longevity/telomere biology
A telomere story is not a longevity treatment.
- Evidence
- Cell, animal/primate, older gerontology, and narrow research-tradition evidence; no robust human healthspan outcomes.
- Access
- Not FDA-approved; reviewed by FDA PCAC for insomnia
- First move
- Sleep/circadian basics, light timing, exercise, metabolic and cardiovascular prevention
503A compounding; high risk · Guide planned
DEC-013
Epitalon
Insomnia treatment
The telomere story is not an insomnia trial.
- Evidence
- No convincing controlled human insomnia evidence matching the public claim.
- Access
- Not FDA-approved; PCAC reviewed insomnia use
- First move
- CBT-I, sleep apnea screen, circadian rhythm workup, evidence-based insomnia care
503A compounding; high risk · Guide planned
DEC-014
Peptide COA
99% pure means safe
A COA can support identity or purity. It cannot prove that an injectable is safe for you.
- Evidence
- Quality-literacy framework, not efficacy evidence.
- Access
- COA varies by vendor/lab and does not establish clinical appropriateness
- First move
- Regulated pharmacy supply, sterile compounding standards, clinician oversight
Framework; varies · Guide planned
DEC-015
FDA / 503A status
If a clinic can get it, it must be proven
Access is not evidence.
- Evidence
- Regulatory-literacy framework based on FDA/PCAC materials.
- Access
- 503A/PCAC review is not approval or efficacy evidence
- First move
- FDA-approved drug pathway, clinical trials, supervised care
Framework; not a route claim · Guide planned
DEC-038
Semaglutide / tirzepatide
Compounded access during shortage or affordability constraints
The evidence may belong to the molecule, but the risk may belong to the source.
- Evidence
- Access/quality row, not an efficacy row.
- Access
- 503A/503B/shortage-dependent access category, source must be verified at time of writing
- First move
- FDA-approved branded supply when accessible; clinician/pharmacy due diligence if compounded
Shortage compounding; varies · Guide planned
DEC-039
Retatrutide
Weight loss / metabolic pipeline drug
Retatrutide belongs in the Atlas precisely because trial-stage is not the same as ready-to-buy.
- Evidence
- Promising human trial-stage evidence; not an approved DIY peptide.
- Access
- Investigational drug category, not gray-market wellness access
- First move
- Approved obesity medications or clinical trial enrollment
Investigational; moderate risk · Guide planned
DEC-040
Retatrutide
Research-use or gray-market retatrutide
Pipeline hype is how evidence leaks into unsafe access.
- Evidence
- Efficacy trial signal does not validate non-prescribed supply; source quality is the main claim problem.
- Access
- Research-use/gray-market access
- First move
- Do not self-source; consider approved options or clinical trials
Gray-market; highest risk · Guide planned
DEC-041
Semaglutide / tirzepatide
Research-use or gray-market GLP-1 products
The evidence may belong to the molecule; the risk may belong to the source.
- Evidence
- Approved-drug evidence does not validate non-prescribed supply, concentration, sterility, or labeling.
- Access
- Gray-market/research-use access
- First move
- FDA-approved branded supply when accessible; clinician/pharmacy due diligence if compounded
Gray-market; highest risk · Guide planned
DEC-042
Semaglutide salt forms
Semaglutide sodium/acetate is basically the same
A similar name is not the same active ingredient.
- Evidence
- FDA states salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than approved semaglutide products and should not be used for compounding.
- Access
- Unapproved/salt-form access problem
- First move
- Avoid salt-form substitutions; use approved or appropriately supervised regulated pathways
Gray-market; highest risk · Guide planned
DEC-043
Retatrutide
Type 2 diabetes / glycemic control
Trial data can be strong before a drug is available medicine.
- Evidence
- Phase 2 and phase 3 human trials support glycemic and weight effects, but regulatory approval/access status remains separate.
- Access
- Investigational drug category, not approved access
- First move
- Approved diabetes/obesity medications or clinical trial enrollment
Investigational; moderate risk · Guide planned
DEC-044
Retatrutide
MASLD / liver fat reduction
Liver-fat signal is exciting; do not translate it into a generic longevity claim.
- Evidence
- Phase 2a substudy shows strong liver-fat reduction by MRI-PDFF; not yet a biopsy-proven MASH/fibrosis-outcome or longevity claim.
- Access
- Investigational drug category, not approved access
- First move
- MASLD workup, weight-loss therapy, cardiometabolic risk management, clinical trial enrollment
Investigational; moderate risk · Guide planned
The one-word problem
When someone says they are on a peptide, that carries about as much clinical information as saying they are taking a pill. Peptides are short amino-acid chains, and the body makes thousands of them. Wellness marketing collapses mechanism, legality, route, human evidence, and efficacy into a single word, then borrows the plausible biology of one peptide to sell all of them.
The peptides grouped together in today's headlines were grouped by a regulatory process, not by a shared mechanism or a shared safety story. BPC-157, Semax, and Epitalon are as different from each other as three unrelated drugs. The honest way through is one peptide, one claim at a time.
How to read the Decoder
The Peptide Decoder above is the heart of this page. Each row is a single peptide paired with a single claim, because the grade changes when the claim changes. The same molecule can have strong evidence for one approved use and thin evidence for the wellness claim attached to it.
Every row keeps the evidence question and the access question apart. Read a row by asking the questions that decide whether a claim holds up.
Name the exact peptide, not the category.
Name the specific claim or use.
Check the route and source category.
Separate human outcome evidence from animal, cell, and mechanism data.
Ask whether the regulatory status is approved, compounded, investigational, research-use-only, or gray-market.
Compare it with the better-studied first move for the same goal.
Access is not evidence
The most common mistake is treating availability as proof. A peptide being compoundable, or a clinic being willing to sell it, is a question of access and policy, not a verdict on whether it helps. FDA review of a peptide for the 503A compounding bulks list is a decision about compounding a bulk substance, not an approval and not an efficacy finding.
This matters most in the metabolic lane, where real medicine and gray-market supply share molecule names. An FDA-approved semaglutide or tirzepatide product, a patient-specific compounded version, a 503B outsourcing-facility product, and a research vial from an online store are different risk categories even when the ingredient sounds similar. The evidence may belong to the molecule while the risk belongs to the source, concentration, sterility, label, and oversight.
Real medicine, interesting mechanism, and marketing
Three buckets sit inside the word peptide. Some peptides are real medicine: semaglutide and tirzepatide have large human trials and approved indications. Some peptides have interesting mechanisms with thin human evidence, like BPC-157 for tissue repair or MOTS-c for metabolism, where the biology is worth studying but the injectable is not yet a treatment. And some marketing simply outruns the evidence, like an insomnia claim built on a telomere story.
Being mechanism-curious and evidence-disciplined are not in tension. Plausible biology is a reason to run trials, not a reason to inject yourself, and pipeline drugs like retatrutide show how strong trial data can exist before a molecule is available medicine.
What to do instead of buying the hype
This guide does not publish doses, stacks, injection technique, reconstitution math, or sourcing. It is meant to make you peptide-literate fast enough to tell medicine from marketing, then route you toward care that has evidence behind it.
Diagnose first. Persistent tendon pain, unexplained weight change, chronic insomnia, and post-stroke deficits each have a real workup.
Ask two questions every timeis this available, and has this been shown to work and be safe in humans for this exact use?
Distrust borrowed evidence from another molecule, route, species, or endpoint.
Start with the better-studied alternative before escalating to an unproven peptide.
Talk to a physician before starting any peptide, especially any injectable.
Clinical lens
How I’d decide
Use this section as a second pass after the main answer, not as homework before you know what the page is saying.
Who it’s for
People trying to understand peptide therapy, BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, GLP-1s, retatrutide, compounded peptides, or research peptides without getting pulled into hype, dosing advice, or vendor marketing.
Who should skip it
Do not use this as a peptide protocol, dosing guide, injection guide, vendor list, or substitute for care. If you are looking for a stack or a source, this is intentionally the wrong page.
Measure before / after
Measure the claim, not the vibe: exact peptide, exact use, route, human evidence, regulatory status, source category, sterility and identity risk, and the better-studied alternative.
What I’d do first
I would start with diagnosis and the better-studied option. If a peptide is still on the table, separate availability from evidence and ask what human outcome data support the exact claim.
What would change my mind
I would upgrade a row when replicated human trials show meaningful outcomes for the exact molecule, route, population, and claim, with a usable safety and quality framework. I would downgrade claims that rely on animal data, borrowed biology, or gray-market access.
Frequently Asked Questions
Are peptides FDA approved?
Some are, and most marketed wellness peptides are not. Insulin, semaglutide, and tirzepatide are FDA-approved peptide drugs for specific indications. Many peptides driving current wellness headlines, including BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax, and Epitalon, are not FDA-approved for clinical use in the United States. Approval is claim-specific and molecule-specific.
Are peptides safe?
There is no single answer because peptide is a format, not a safety class. Approved peptide drugs have human safety data behind their labeled uses. Many gray-market peptides have little or no human safety data, and injectable risk also depends on sterility, purity, concentration, and what is actually in the vial.
What is a compounded peptide?
A compounded peptide is prepared by a pharmacy outside standard mass manufacturing. Compounding may happen under 503A patient-specific compounding or 503B outsourcing-facility pathways, but compounding is about access and preparation. It is not FDA approval and it is not proof of efficacy.
Do research peptides work?
It depends on the peptide and the claim. For several popular peptides, the strongest data are still preclinical, meaning cells, animals, or tiny uncontrolled human series. Research-use-only labeling also signals a product not intended or verified for human injection.
What is the difference between a peptide and a peptide drug?
A peptide is any short chain of amino acids. A peptide drug has gone through the drug pathway for an approved indication, with human trials, a defined label, and regulated manufacturing. This guide is built around that distinction.
References & citations
- 1.FDA July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page
- 2.FDA PCAC briefing introduction for reviewed free-base and acetate peptide substances
- 3.FDA: Bulk Drug Substances Used in Compounding Under Section 503A
- 4.FDA: Bulk Drug Substances Used in Compounding Under Section 503B
- 5.FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- 6.Vasireddi et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. HSS Journal, 2025
- 7.Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021
- 8.Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM, 2023
Related Guides
Clinical use
Bring a specific peptide claim, not the word peptide.
A useful peptide decision starts with the exact molecule, exact claim, human evidence, regulatory status, and source risk. The category name is not enough.